Arvinas Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
430
- Stock Symbol
-
ARVN
- Investments
-
1
- Share Price
-
$8.43
- (As of Friday Closing)
Arvinas General Information
Description
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Contact Information
Website
www.arvinas.comCorporate Office
- 5 Science Park
- 395 Winchester Avenue
- New Haven, CT 06511
- United States
Corporate Office
- 5 Science Park
- 395 Winchester Avenue
- New Haven, CT 06511
- United States
Arvinas Timeline
Arvinas Stock Performance
As of 14-Mar-2025, Arvinas’s stock price is $8.43. Its current market cap is $580M with 68.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $8.43 | $8.55 | $7.91 - $45.77 | $580M | 68.8M | 1.59M | -$2.77 |
Arvinas Financials Summary
As of 31-Dec-2024, Arvinas has a trailing 12-month revenue of $263M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 197,130 | 197,130 | 1,804,339 | 556,113 |
| Revenue | 263,400 | 263,400 | 78,500 | 131,400 |
| EBITDA | (246,500) | (246,500) | (396,000) | (254,800) |
| Net Income | (198,900) | (198,900) | (367,300) | (282,500) |
| Total Assets | 1,091,400 | 1,091,400 | 1,304,600 | 1,268,800 |
| Total Debt | 9,700 | 9,700 | 3,200 | 5,500 |
Arvinas Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Arvinas Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Arvinas Comparisons
Industry
Financing
Details
Arvinas Competitors (93)
One of Arvinas’s 93 competitors is Alector, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alector | Formerly VC-backed | South San Francisco, CA | ||||
| Prelude Therapeutics | Formerly VC-backed | Wilmington, DE | ||||
| Pyxis Oncology | Formerly VC-backed | Boston, MA | ||||
| Iovance Biotherapeutics | Corporation | San Carlos, CA | ||||
| Auron Therapeutics | Venture Capital-Backed | Newton, MA |
Arvinas Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Arvinas Patents
Arvinas Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250009737-A1 | Compounds and methods for the targeted degradation of androgen receptor | Pending | 30-Jun-2023 | ||
| US-20240336566-A1 | Crystalline forms of a compound for the targeted degradation of the androgen receptor | Pending | 30-Mar-2023 | ||
| US-20240287101-A1 | Cereblon-based kras degrading protacs and uses related thereto | Pending | 26-Jan-2023 | ||
| US-20240335444-A1 | Modulators of bcl6 proteolysis and associated methods of use | Pending | 09-Jan-2023 | ||
| US-20240180900-A1 | Compounds and methods for the targeted degradation of androgen receptor | Pending | 24-Oct-2022 | A61K31/496 |
Arvinas Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Arvinas Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Arvinas Investments (1)
Arvinas’s most recent deal was a Joint Venture with Oerth Bio. The deal was made on 15-Jul-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Oerth Bio | 15-Jul-2019 | Joint Venture | Biotechnology |
Arvinas ESG
Risk Overview
Risk Rating
Updated December, 06, 2022
26.24 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,946
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Biotechnology
Subindustry
of 366
Rank
Percentile
Arvinas Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Arvinas (License of ARV-766 in New Haven, Connecticut) | New Haven, CT |
Arvinas FAQs
-
When was Arvinas founded?
Arvinas was founded in 2013.
-
Where is Arvinas headquartered?
Arvinas is headquartered in New Haven, CT.
-
What is the size of Arvinas?
Arvinas has 430 total employees.
-
What industry is Arvinas in?
Arvinas’s primary industry is Drug Discovery.
-
Is Arvinas a private or public company?
Arvinas is a Public company.
-
What is Arvinas’s stock symbol?
The ticker symbol for Arvinas is ARVN.
-
What is the current stock price of Arvinas?
As of 14-Mar-2025 the stock price of Arvinas is $8.43.
-
What is the current market cap of Arvinas?
The current market capitalization of Arvinas is $580M.
-
What is Arvinas’s current revenue?
The trailing twelve month revenue for Arvinas is $263M.
-
Who are Arvinas’s competitors?
Alector, Prelude Therapeutics, Pyxis Oncology, Iovance Biotherapeutics, and Auron Therapeutics are some of the 93 competitors of Arvinas.
-
What is Arvinas’s annual earnings per share (EPS)?
Arvinas’s EPS for 12 months was -$2.77.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
